A Japanese Case of Familial Hypercholesterolemia with a Protein-truncating Variant in LDLR and a PCSK9 Variant without Significant Atherosclerosis but Showing Remarkable Achilles Tendon Thickening

被引:1
|
作者
Minamizuka, Takuya [1 ]
Kobayashi, Junji [1 ]
Tada, Hayato [2 ]
Koshizaka, Masaya [1 ]
Maezawa, Yoshiro [1 ]
Ono, Hiraku [1 ]
Yokote, Koutaro [1 ]
机构
[1] Chiba Univ, Grad Sch Med, Endocrine Metab Hematol Geriatr Med, Chiba, Japan
[2] Kanazawa Univ, Cardiovasc Med, Grad Sch Med Sci, Kanazawa, Japan
关键词
heterozygous familial hypercholesterolemia; a protein-truncating variant in the LDLR; Lp(a); computerized tomography (CT) coronary angiogram; PCSK9; variant; CARDIOVASCULAR-DISEASE; IMPACT;
D O I
10.2169/internalmedicine.2726-23
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The patient was a 54-year-old woman with familial hypercholesterolemia and remarkable Achilles tendon thickening. At 20 years old, the patient had a total cholesterol level of approximately 300 mg/dL. She started receiving rosuvastatin (5 mg/day) for low-density lipoprotein cholesterol (LDL-C) 235 mg/dL at 42 years old, which was increased to 10 mg/day at 54 years old, decreasing her serum LDL-C level to approximately 90 mg/dL. The serum Lp(a) level was 9 mg/dL. A computed tomography coronary angiogram showed no significant stenosis. Next-generation sequencing revealed a frameshift variant in LDL receptor (LDLR) (heterozygous) and a missense variant in proprotein convertase subtilisin/kaxin type 9 (PCSK9) (heterozygous). Continued statin therapy, in addition to low Lp(a) and female sex, can help prevent cardiovascular disease.
引用
收藏
页码:2137 / 2142
页数:6
相关论文
共 6 条
  • [1] A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene
    Tada, Hayato
    Okada, Hirofumi
    Nomura, Akihiro
    Nohara, Atsushi
    Takamura, Masayuki
    Kawashiri, Masa-aki
    INTERNAL MEDICINE, 2020, 59 (06) : 783 - 787
  • [2] PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 (PCSK9) V4I VARIANT WITH LDLR MUTATIONS MODIFIES THE PHENOTYPE OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    Hori, M.
    Ohta, N.
    Takahashi, A.
    Ogura, M.
    Makino, H.
    Tamanaha, T.
    Miyamoto, Y.
    Harada-Shiba, M.
    ATHEROSCLEROSIS, 2016, 252 : E35 - E36
  • [3] Identification of a novel LDLR p.Glu179Met variant in Thai families with familial hypercholesterolemia and response to treatment with PCSK9 inhibitor
    Pussadhamma, Burabha
    Wongvipaporn, Chaiyasith
    Wutthimanop, Atthakorn
    Nuinoon, Manit
    Porntadavity, Sureerut
    Jeenduang, Nutjaree
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [4] THE UCL LDLR, PCSK9 & LDLRAP1 VARIANT DATABASES: UPDATE, ANALYSIS & OVERVIEW OF THREE PUBLICLY AVAILABLE FAMILIAL HYPERCHOLESTEROLEMIA GENE DATABASES
    Leigh, S.
    Jakubcova, T.
    Whittall, R. A.
    Humphries, S. E.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 34 - 34
  • [5] Achilles Tendon Xanthoma Thickness and Carotid Intima-Media Thickness in a Patient With Heterozygous Familial Hypercholesterolemia on PCSK9 Inhibition: A Case Report and Literature Review
    Alam, Loba
    Lasam, Glenmore
    Fishberg, Robert
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
  • [6] Protein structural insights into a rare PCSK9 gain-of-function variant (R496W) causing familial hypercholesterolemia in a Saudi family: whole exome sequencing and computational analysis
    Shaik, Noor Ahmad
    Al-Shehri, Najla
    Athar, Mohammad
    Awan, Ahmed
    Khalili, Mariam
    Al Mahadi, Hadiah Bassam
    Hejazy, Gehan
    Saadah, Omar I. I.
    Al-Harthi, Sameer Eida
    Elango, Ramu
    Banaganapalli, Babajan
    Alefishat, Eman
    Awan, Zuhier
    FRONTIERS IN PHYSIOLOGY, 2023, 14